Patents Examined by Bruck Kifle
  • Patent number: 11325915
    Abstract: This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: May 10, 2022
    Assignee: The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Richard Marais, Caroline Springer, Dan Niculescu-Duvaz, Natalie Miller, Mohammed Aljarah, Alfonso Zambon, Leo Leung, Deborah Smithen, Michael Brown, Haoran Tang
  • Patent number: 11325917
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 10, 2022
    Assignee: VALO HEALTH, INC.
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
  • Patent number: 11319314
    Abstract: The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Stefan Berchtold, Guido Galley, Annick Goergler, Roland Jakob-Roetne, Daniela Krummenacher, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Rosa Maria Rodriguez Sarmiento, Christian Schnider
  • Patent number: 11312721
    Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 26, 2022
    Assignee: AGENEBIO, INC.
    Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang
  • Patent number: 11306096
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer. Described herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d each independently represent hydrogen, optionally substituted C1-C6 alkyl or R1a and R1b together form an optionally substituted C3-C6 cycloalkyl ring, or R1c and R1d together form an optionally substituted C3-C6 cycloalkyl ring; A is a 5 membered nitrogen-containing aromatic ring and is substituted with at least one optionally substituted 5 to 10 membered monocyclic or bicyclic heteroaryl or aryl ring attached through an optional linker.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: April 19, 2022
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • Patent number: 11299477
    Abstract: The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: April 12, 2022
    Assignee: Laurus Labs Limited
    Inventors: Satyanarayana Chava, Seeta Rama Anjaneyulu Gorantla, Venkata Sunil Kumar Indukuri, Sanjay Kumar Dehury, Nagaraju Mekala, Jahangeer Baba Shaik, Durga Prasad Kuchipudi
  • Patent number: 11286263
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: March 29, 2022
    Assignees: The Broad Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Steven James Ferrara, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Laura Furst, Guo Wei, Patrick Ryan McCarren, Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Sack, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning
  • Patent number: 11279678
    Abstract: Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, bis-, tri-, tetra- or penta-substituted on a phenyl group; a linking group L1 is an alkyl or alkenyl group having 1, 2, 3, or 4 carbon atoms, a linking group L2 is oxygen, or an alkyl or alkoxy group having 1, 2, 3, or 4 carbon atoms, or an amino acid, or an alkyl group having 1, 2, 3, or 4 carbon atoms containing an amino moiety, or a furyl group, and an X group is O or —NH—. Further disclosed is a method for preparing such a derivative and a use of the same in the treatment of cancer, tumor diseases, and diseases caused by abnormal neovascularization in a human or non-human mammal, and a medicament or a composition containing the 5-fluorouracil derivative.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: March 22, 2022
    Inventors: Fanhong Wu, Jinwen Huang, Jiujiu Zhou, Wan Pang, Lei Zhao, Zhonglin Ma, Zhikai Zhang, Xiaodong Yu, Jianyue Wu
  • Patent number: 11267821
    Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 8, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiaki Ohashi, Yoshihiko Norimine, Tamaki Hoshikawa, Yu Yoshida, Yoshihisa Kobayashi, Nobuhiro Sato, Koji Hagiwara, Nobuaki Sato, Shinsuke Hirota, Takaaki Harada, Hikaru Yoshimura
  • Patent number: 11267805
    Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: March 8, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: George P. Luke, Stephen Hubbs, Matthew W. Martin, Shawn E. R. Schiller, Robert Wenslow, Yawei Shi, Jun Huang
  • Patent number: 11261174
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 1, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Jun Li, Yan Shi, Ying Wang, Hao Zhang, Lawrence J. Kennedy, Steven J. Walker, Ramesh Babu Reddigunta
  • Patent number: 11254657
    Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 22, 2022
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Lan Huang, Aniruddh Singh
  • Patent number: 11248003
    Abstract: A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 15, 2022
    Assignee: ONCOBIX CO., LTD.
    Inventors: Sung-Eun Kim, Sunho Lee, Rengasamy Rajesh, Dae Ho Kang, Hyung Chui Ryu, Jae-Sun Kim, Sangryul Lee, Kyong Cheol Kim, Jin Kyung Rho, Jae Cheol Lee
  • Patent number: 11247991
    Abstract: The present application provides bifunctional compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 8 (CDK8). The present application also relates to methods for the targeted degradation of CDK8 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 which can be utilized in the treatment of disorders modulated by CDK8.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: February 15, 2022
    Inventors: Nathanael S. Gray, Tinghu Zhang, Calla M. Olson, Yanke Liang, Nicholas Kwiatkowski
  • Patent number: 11242359
    Abstract: A modular tetrazine platform, can be used as diagnostic, theragnostic agent and/or medicinal product. An inverse electron demand Diels-Alder reaction can be used for synthesizing bifunctionalized tetrazines, which can be obtained from monofunctionalised tetrazines.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: February 8, 2022
    Inventors: Victor Goncalves, Franck Denat, Claire Bernhard, Coline Canovas
  • Patent number: 11242340
    Abstract: Provided are four crystal forms, A, B, C and D, of demethyleneberberine hydrochloride, and a preparation method therefor, and further provided are X-ray powder diffraction characteristic absorption peaks, infrared absorption peaks and DSC spectra of the four crystal forms. The X-ray powder diffraction characteristic diffraction peaks of the crystal forms are at about 8.205°, 8.805°, 10.817°, 14.835°, 15.479°, 16.668°, 17.492°, 18.529°, 20.656°, 21.536°, 23.538°, 25.657°, 26.192°, and 28.808°. A preparation method for the four crystal forms of the demethyleneberberine hydrochloride is also involved. The preparation method has a simple process, a high yield and a low cost; and has a high product purity and a stable quality.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 8, 2022
    Inventors: Yubin Zhang, Yuanqiang Zhang, Miao Zhang, Qingxia Li
  • Patent number: 11242349
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
  • Patent number: 11245078
    Abstract: Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 8, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Diajun Feng
  • Patent number: 11220507
    Abstract: The present invention relates to a process for the preparation of rucaparib; the invention also refers to novel intermediates of synthesis as well as their use in the preparation of i.a. rucaparib.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: January 11, 2022
    Assignee: Advitech Advisory and Technologies SA
    Inventors: Brent Christopher Beck, Joe B. Perales, Jason D. Speake, Ilaria Ferrando
  • Patent number: 11220506
    Abstract: Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3K? related disorders or diseases by using the compound disclosed herein.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 11, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Jing Li, Haibo Zhao, Zhiwei Wang